|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||32.50 - 34.05|
|52 Week Range||28.00 - 43.60|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Activist investor Voce Capital nominated two directors to Natus Medical’s board, launching a fight over decision-making at the $1 billion neurological and infant diagnostics company.
Natus Medical Inc (NASDAQ:BABY) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on February 1. Additionally, the rate of outflows appears to be accelerating.
When Natus Medical Incorporated (NASDAQ:BABY) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...
On a per-share basis, the Pleasanton, California-based company said it had a loss of 22 cents. Earnings, adjusted for amortization costs and costs related to mergers and acquisitions, came to 42 cents ...
It seems to be a wise decision for investors to drop Natus Medical (BABY) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
SMART Global Holdings, Natus Medical, Interactive Brokers Group, Renasant and GATX highlighted as Zacks Bull and Bear of the Day
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Natus Medical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
A Relative Strength Rating upgrade for Natus Medical shows improving technical performance. Will it continue?
The healthcare industry, in particular, has been facing multiple issues, with the Obamacare-repeal saga dominating the headlines. This has undoubtedly been the latest buzz in the MedTech space. AdvaMed, a leading American medical device trade association, had referred to the medical device tax as a ‘significant drag on medical innovation’.
In the wake of the volatile political scenario and taking a few favorable metrics into account, these MedTech stocks stand out as the most suitable picks.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding BABY is favorable, with net inflows of $6.00 billion.